Skip to main content
PsoriasisSkin

What this study is

The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.

Study details

Official title
CorEvitas Psoriasis (PSO) Registry
Sponsor
CorEvitas
Conditions
Psoriasis
Enrolling
10,000 people
Starts
2015-04
Est. completion
2100-12
Record
View on ClinicalTrials.gov ↗